Loading organizations...
Loading organizations...
Sempre Health is a technology company.
Sempre Health has raised $11.0M across 2 funding rounds.
Sempre Health has raised $11.0M in total across 2 funding rounds.
Sempre Health rewards patients for being responsible for their health by providing discounts on medications through a behavior-based, dynamic pricing model.
# Sempre Health: Behavior-Based Pricing for Medication Affordability
Sempre Health is a healthcare technology company that makes prescription medications more affordable and improves patient adherence through dynamic, behavior-based pricing.[1][2] Founded in 2015, the company partners with health plans, pharmacy benefit managers (PBMs), and pharmaceutical manufacturers to deliver personalized discounts on prescription drugs that adjust based on patients' medication refill behaviors.[1][2] The core problem Sempre addresses is significant: nearly 30% of Americans skip prescriptions due to cost, driving an estimated $290 billion in avoidable medical expenses annually.[6]
The company operates a B2B2C model where it integrates with the existing healthcare infrastructure to apply real-time discounts at the point of sale and through SMS engagement.[1][2] By aligning incentives across patients, payers, and pharmaceutical companies, Sempre creates a system where patients save money on medications, health plans reduce overall healthcare spending through improved adherence, and pharma manufacturers benefit from better patient persistence on their drugs. The company has raised more than $43 million in funding and operates from San Francisco, positioning itself within a leading hub for healthcare innovation and venture capital.[2]
Sempre Health was founded in 2015 by two entrepreneurs with a vision to fundamentally change medication affordability.[3] The founding team, led by CEO Anurati Mathur, recognized that medication non-adherence—driven largely by cost barriers—represented a massive inefficiency in the healthcare system. Early traction came through strategic partnerships: by 2018, Sempre had secured partnerships with more than 15 pharmaceutical manufacturers and payers, including a notable collaboration with Novo Nordisk to bring dynamic discounts to diabetes patients.[3]
The company's Series A funding round of $8 million, announced in 2018, validated the market opportunity and the team's execution. Investors like Rethink Impact (the largest US-based impact venture capital firm investing in female entrepreneurs) and Social Capital recognized that Sempre's multi-year pharmaceutical and health insurance partnerships had already demonstrated dramatic impact on drug adherence.[3] This early validation set the stage for scaling the platform across the U.S. healthcare system.
Sempre Health operates at the intersection of three major healthcare trends: the digital health revolution, the shift toward value-based care, and the growing focus on health equity and affordability. The timing is critical—policymakers, payers, and patients are increasingly demanding solutions to the medication non-adherence crisis, which costs the U.S. healthcare system nearly $300 billion annually in preventable hospitalizations and excess spending.[3]
The company exemplifies a broader movement toward behavioral economics in healthcare, where technology platforms use incentives and engagement to drive better health outcomes rather than relying on traditional clinical interventions alone. Sempre's partnerships with major PBMs like Prime Therapeutics and health plans like Blue Cross NC demonstrate that the healthcare establishment is ready to adopt these models at scale.[6]
By solving a problem that affects millions of Americans—the choice between affording medications and paying other bills—Sempre influences the broader ecosystem by proving that technology-enabled, behavior-based solutions can align financial incentives across the entire healthcare value chain. This approach has potential applicability beyond the U.S. market, though the company currently focuses domestically.[1]
Sempre Health is well-positioned for continued growth as medication affordability becomes an increasingly urgent policy and consumer priority. The company's expansion of partnerships with major PBMs and health plans suggests momentum toward becoming a standard tool in the healthcare benefits infrastructure. Future growth will likely depend on demonstrating sustained clinical outcomes and cost savings at scale, expanding into adjacent chronic disease management areas, and potentially exploring international markets where medication adherence challenges mirror those in the U.S.
The broader trend working in Sempre's favor is the healthcare industry's recognition that affordability and adherence are inseparable—and that technology-enabled, incentive-aligned solutions can solve both simultaneously. As health plans and pharma manufacturers face mounting pressure to demonstrate value and improve patient outcomes, platforms like Sempre that deliver measurable improvements in adherence and cost savings will become increasingly central to healthcare strategy.
Sempre Health has raised $11.0M in total across 2 funding rounds.
Sempre Health's investors include BCF Ventures, Bessemer Venture Partners, Metanoia, Rainfall Ventures, Social Capital, Tom Williams.
Sempre Health has raised $11.0M across 2 funding rounds. Most recently, it raised $8.0M Series A in August 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2018 | $8.0M Series A | BCF Ventures, Bessemer Venture Partners, Metanoia, Rainfall Ventures, Social Capital, Tom Williams | |
| May 1, 2016 | $3.0M Seed | BCF Ventures, Bessemer Venture Partners, Metanoia, Rainfall Ventures, Social Capital, Tom Williams |